Rash Risk: Finasteride vs. Tadalafil
Finasteride can cause rash, while tadalafil rarely causes rash—finasteride is the more likely culprit between these two medications.
Finasteride and Rash
Finasteride is explicitly listed as causing rash as a recognized side effect:
- The 2025 AUA guideline specifically identifies rash as one of the more commonly occurring side effects from finasteride 1
- In the FDA-approved drug label, rash occurred in 0.5% of finasteride-treated patients in Year 1 (compared to 0.2% with placebo), and 0.5% in Years 2-4 (compared to 0.1% with placebo) 2
- Case reports document specific dermatologic reactions including photosensitivity reactions with desquamating facial eruptions 3 and psoriasiform drug eruptions developing within one week of starting finasteride 4
Clinical Presentation of Finasteride-Related Rash
The rash patterns associated with finasteride include:
- Photosensitivity reactions presenting as desquamating eruptions on sun-exposed areas like the face, which improve within 2 weeks of drug withdrawal 3
- Psoriasiform eruptions that can develop rapidly (within one week) and present extensively 4
- Localized reactions when using topical formulations, including scalp pruritus, burning, irritation, contact dermatitis, and erythema 5
Tadalafil and Rash
Tadalafil has a much lower association with rash:
- The FDA drug label for tadalafil lists rash as occurring in less than 2% of patients in controlled trials, with the causal relationship uncertain 6
- The 2025 AUA guideline discussing tadalafil for chronic pelvic pain syndrome does not mention rash as a notable side effect 1
- Postmarketing surveillance identified hypersensitivity reactions including urticaria, Stevens-Johnson syndrome, and exfoliative dermatitis as rare events with tadalafil 6
Important Distinction
While tadalafil can theoretically cause severe cutaneous reactions (Stevens-Johnson syndrome, exfoliative dermatitis), these are extremely rare postmarketing events 6. In contrast, finasteride-associated rash is a recognized, more commonly occurring adverse effect documented in clinical trials 2.
Clinical Management Approach
If a patient develops a rash while taking both medications:
- Consider finasteride as the more likely causative agent given its higher incidence and better-documented association 1, 2
- Discontinue the suspected medication and monitor for improvement within 2 weeks 3
- For mild rashes, some clinicians manage with antihistamines while continuing therapy, though this approach is controversial 7
- Immediately discontinue either medication if severe cutaneous manifestations develop (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome) 7, 6
Critical Warning Signs
Stop the medication immediately if the patient develops: